Biocon reports positive results from its global phase 3 study with INSUGEN

31 Oct 2012 Evaluate

Biocon, Asia’s premier biotechnology company, has reported positive results from the Global Phase 3 study for its Recombinant Human Insulin (INSUGEN), in Type 1 diabetes mellitus (T1DM) patients, demonstrates comparable safety and efficacy with the innovator product.

This multi-center, randomized study was conducted in nearly 300, T1DM patients, to compare efficacy, safety and immunogenicity of the company’s Regular human insulin (Insugen R) and lsophane human Insulin (Insugen N) against the innovator products (Actrapid and Insulatard) sourced from Europe.

The Part 2 of the study to demonstrate additional safety and immunogenicity over one year is ongoing and is expected to be completed by next year with the final results expected in H1, FY14.

The above data from this ongoing study along with extensive physico-chemical and biological characterization and PK-PD (pharmacokinetic & pharmaco-dynamic) data generated to date comparing Insugen-R & Insugen-N with the innovator products will enable Biocon to submit a robust dossier for marketing authorization in EU and other global markets.

Biocon produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies.

Biocon Share Price

392.80 4.55 (1.17%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×